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1  |  INTRODUC TION AND A HISTORIC AL 
TRIBUTE
The concept of allergen- specific immunotherapy (AIT) was de-
scribed over a hundred years ago for treatment of grass pollen– 
induced hayfever. Bostock in 1819 delineated hayfever as a 
seasonal illness characterized by airway catarrh, and Dunbar in 
1903 associated it with “pollen toxin”.1 Dunbar described the 
muco- cutaneous symptoms in hayfever and that injection of 
“pollen toxin” in animals induced production of neutralizing an-
tibodies. In a landmark publication in The Lancet in 1911, Noon 
elegantly described that prophylactic pre- seasonal inoculation of 
“pollen toxin” induced “active immunity” against hayfever.1 The 
concept of allergen challenge, then described as “sensitiveness,” 
and how this was altered following repeated inoculation of “pollen 
toxin” was ingeniously employed to obtain an objective read out 
of therapeutic benefit. A standardized pollen extract was manu-
factured by Dunbar's method that involved extraction in distilled 
water, by repeated thawing and freezing.1 The potency of differ-
ent pollens was compared with a conjunctival challenge procedure, 
and it was established that Phleum pratense was most potent among 
different grass species in England. Noon developed a protocol of 
incremental subcutaneous inoculation of “pollen toxin” at regular 
intervals and discovered enhancement of “resistance” as evidenced 
by a “conjunctival challenge”.1 Noon administered a relatively small 
starting dose as 1/3rd of the minimal dose that elicited a conjuncti-
val response to challenge.
This work was carried forward by Freeman2 who inoculated 20 
patients with pollen extract and described therapeutic efficacy in 
16 patients. Frankland and Augustin conducted the first “controlled” 
clinical trial for hayfever and seasonal asthma and showed efficacy 
of “crude” and “purified pollen extracts”.3
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Allergen- specific immunotherapy (AIT) is the only means of altering the natu-
ral immunological course of allergic diseases and achieving long- term remission. 
Pharmacological measures are able to suppress the immune response and/or ame-
liorate the symptoms but there is a risk of relapse soon after these measures are 
withdrawn. Current AIT approaches depend on the administration of intact allergens, 
often comprising crude extracts of the allergen. We propose that the challenges aris-
ing from current approaches, including the risk of serious side- effects, burdensome 
duration of treatment, poor compliance and high cost, are overcome by application of 
peptides based on CD4+ T cell epitopes rather than whole allergens. Here we describe 
evolving approaches, summarize clinical trials involving peptide AIT in allergic rhinitis 
and asthma, discuss the putative mechanisms involved in their action, address gaps in 
evidence and propose future directions for research and clinical development.
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2  |    WRAITH And KRISHnA
The fundamental principle underpinning AIT has not changed 
since it was first described in 1911, but great strides have been 
made with respect to standardization, purification and optimiza-
tion of treatment protocols in order to maintain safety and max-
imize therapeutic benefit. The aim of AIT is to reduce allergic 
mucosal inflammation by induction of immune tolerance, thereby 
alleviating symptoms and improving health- related quality of life. 
Administration of crude allergen extracts for AIT is associated with 
a risk of provoking an immediate (type- 1) hypersensitivity reaction 
due to recognition of antigen/s or allergen by specific IgE on the 
surface of mast cells and basophils. Hence, efforts have focussed 
on development of novel approaches involving administration of 
modified allergens (recombinant allergens or peptides) to reduce/
circumvent IgE binding, that is reduce allergenicity but maintain 
immunogenicity.
An ideal AIT product should meet the following criteria: cost- 
effective, minimal allergenicity and maximal immunogenicity and 
tolerogenicity, needing few doses or a short treatment course with 
ease of administration (preferably self- administration unsupervised), 
providing long- term therapeutic efficacy and importantly carrying 
minimal side- effects in terms of provoking local and systemic allergic 
reactions.
2  |  CURRENT APPROACHES IN CLINIC AL 
PR AC TICE
2.1  |  Treatment modalities
The two main modalities currently employed world- wide for AIT in 
allergic rhinoconjunctivitis (ARC) include subcutaneous injection 
immunotherapy (SCIT) and sublingual immunotherapy (SLIT). As 
per current British and European guidelines, these treatments are 
offered to patients with moderate- severe ARC that is either unre-
sponsive or partially responsive to standard pharmacotherapy.4,5 An 
important recent development has been the recommendation by the 
European Academy of Allergy and Clinical Immunology (EAACI) and 
Global Initiative for Asthma (GINA 2020; https://ginas thma.org/wp- 
conte nt/uploa ds/2020/06/GINA- 2020- report_20_06_04- 1- wms.
pdf) regarding use of AIT in house dust mite– driven allergic asthma.6 
HDM SLIT tablets have been recommended for adults as an “add- on” 
or adjunct therapy in those with controlled or partially controlled 
disease6 with an aim to reduce acute attacks. HDM SLIT drops have 
been similarly recommended for children with well- controlled dis-
ease in order to reduce medication use and better control of asthma 
symptoms. Similarly, HDM SCIT has been recommended for adults 
with well- controlled disease for better symptomatic control and 
reduction of medication usage.6 It has been acknowledged by the 
authors of EAACI guidelines that the quality of evidence, however, 
is fairly limited at present with respect to use of AIT to treat chronic 
asthma. Well- designed studies are needed to delineate the role for 
AIT in the context of mild- moderate asthma endotypes7 (type- 2 
“high” and non- type- 2 or type- 2 “low”) based on predominant 
underlying inflammatory pathways, although it is likely to be more 
effective in type- 2 “high.”
2.2  |  Safety aspects
Safety remains an important concern, as uncontrolled asthma is an 
important risk factor for fatal and near fatal systemic allergic reac-
tions to AIT. Hence, patient selection is paramount, and AIT is re-
stricted to specialist use only in a secondary care setting. As regards 
UK practice, use of AIT in ARC is a relative contraindication in patients 
with concomitant mild- moderate well- controlled asthma as per The 
British Society for Allergy and Clinical Immunology (BSACI) guide-
lines and an absolute contraindication in those with uncontrolled, 
severe or brittle asthma.5 Furthermore, AIT is not recommended for 
the treatment of chronic asthma per se in the UK practice.
Several clinical trials with different AIT products have high-
lighted safety and efficacy (short- term and long- term) of SCIT and 
SLIT, particularly for grass pollen, birch pollen, ragweed and house 
dust mite.8– 12 They involve administration of a standardized intact 
whole allergen extract, although modified allergens (allergoids and 
polymerized extracts) have also been shown to be safe and effec-
tive. SCIT formulations include aqueous and depot (aluminium hy-
droxide or tyrosine to enhance immunogenicity) preparations. SLIT 
is available as dissolving tablets or drops. Systematic review and 
meta- analysis of SCIT and SLIT for ARC have shown that they have a 
modest/moderate therapeutic benefit.11,12
Whilst mild oropharyngeal reactions are relatively frequent and 
commonly associated with SLIT, systemic reactions and anaphylaxis 
are very rare.4,5 SCIT is associated with the risk of systemic reactions 
and anaphylaxis, and rarely fatal anaphylaxis could occur.4,5,13– 15 The 
SCIT national surveillance project from North America reported 7 
fatalities between 2004 and 2017 out of 54.7 million injection vis-
its. SCIT- associated systemic reactions occurred in 0.1% of injection 
visits, involving varying severity with greater risks associated with 
accelerated (rush and ultra- rush) protocols.15 Hence, preference is to 
employ a conventional up dosing protocol involving 12 weekly visits, 
particularly in the UK, where most whole allergen extracts for SCIT 
are currently unlicensed.5
2.3  |  Practical aspects
There are recognized logistic issues with SCIT and SLIT.4,5 SCIT 
should be administered under specialist supervision and in second-
ary care with access to critical care should anaphylaxis occur. Hence, 
there are overhead expenses attached to administration of SCIT. 
It involves considerable time commitment for patients with multi-
ple visits and with a waiting time for an hour following each injec-
tion. SLIT, on the other hand, is initiated in hospital, and patients 
are trained for self- administration. Standard recommended dura-
tion of both treatments is 3 years. Those failing to show therapeutic 
response can be identified early and treatment may be withdrawn. 
    |  3WRAITH And KRISHnA
Compliance to treatment has been highlighted as a concern in a real- 
life setting. A study from The Netherlands in 6486 patients (2789 
SCIT and 3690 SLIT)16 reported an overall 18% compliance with 
respect to completion of the 3- year course of standard treatment 
(median 1.7 and 0.6 years, respectively, for SCIT and SLIT). One of 
the predictors for discontinuation was the prescriber, with patients 
more likely to persist with treatment with a general practitioner than 
with a specialist.
2.4  |  Other AIT modalities
Other approaches that have shown some promise include AIT with 
adjuvants (TLR- 4 agonist, monophosphoryl lipid A; TLR- 9 agonist, 
bacterial DNA oligonucleotides containing a CpG motif), combina-
tion of AIT with omalizumab, recombinant Bet v 1, recombinant B 
cell epitope- based vaccine, comprising a recombinant hybrid grass 
allergen mix conjugated with a hepatitis B domain surface.17– 23 
Other routes of administration have also been attempted including 
intradermal, epicutaneous and intralymphatic24– 26 routes. There 
have been several studies during the last 2 decades investigating 
efficacy and safety of short and long contiguous overlapping pep-
tides (COPs) targeting dominant T cell epitopes of major allergens 
as an alternative to employing intact or whole allergens for AIT. 
Long COPs represent fragments of overlapping peptides cover-
ing the entire sequence of respective allergen, thereby preserving 
the relevant peptides for T cell recognition, but carrying an advan-
tage of lacking conformation of the whole molecule to prevent IgE 
binding on the surface of mast cells of basophils. Similarly, short 
peptides, generally comprising single T cell epitopes, are usually 
8– 20 amino acids. Selection of the correct sequence and optimiz-
ing the length of peptide is critical to safety, success and cost of 
peptide AIT.
The main aim of this review is to critically appraise AIT involving 
peptide- based treatment for ARC. We will review clinical trials that 
have investigated the therapeutic efficacy and safety of peptide AIT 
for ARC, challenges associated with this modality, and describe pu-
tative mechanisms and future directions.
3  |  R ATIONALE BEHIND PEPTIDE 
IMMUNOTHER APY
Peptide AIT in allergic airway disease rests on two fundamental prin-
ciples,27,28 (a) a pivotal role for T cells in orchestrating chronic allergic 
mucosal inflammation in ARC and asthma and (b) circumventing IgE- 
mediated recognition and cross- linking with allergen on the surface 
of mast cells and basophils, the mechanism underpinning systemic 
type- 1 hypersensitivity reactions to whole allergen AIT.
Predefined and well- mapped short peptides (SPs) or long COPs 
of major allergens representing dominant T cell epitopes, with the 
ability to bind to a vast array of HLA class II alleles, can be adminis-
tered at regular intervals, either intradermally or subcutaneously to 
induce allergen- specific T cell tolerance.27,28 This concept has been 
also been tested with some success in the context of autoimmune 
diseases where there are recognized target antigens such as in au-
toimmune liver diseases, rheumatoid arthritis, type- I diabetes, mul-
tiple sclerosis and Graves’ disease.28– 34 Targeting pathogenic T cells 
in organ- specific autoimmune diseases with T cell epitopes induces 
antigen- specific regulatory T cells and this strategy is under evalua-
tion in clinical trials.
From a logistical and cost viewpoint, short peptides can be man-
ufactured in a standardized fashion with low production costs and 
are relatively stable in a lyophilized form at room temperature.35 
Also, cost of production of peptide- based therapeutics is low since 
mass production of high purity product is achievable. Therefore, as 
soon as development costs are recovered, we predict that treat-
ments for common allergic disorders will be inexpensive.
4  |  ANALYSIS OF CLINIC AL TRIAL S AND 
STUDIES INVOLVING PEPTIDE AIT FOR 
ALLERGIC AIRWAY DISE A SES
4.1  |  Framework for peptide AIT
Phase 1– 3 clinical trials have been conducted to investigate the ef-
ficacy and safety of peptide AIT for allergic airway diseases. These 
have mainly focussed on major allergens including birch pollen,36,37 
grass pollen38– 44 or cat.45– 56 The main approach taken in these 
studies has been to administer SPs or COPs over 4– 6 weeks, either 
starting at a relatively low dose with structured escalation to reach 
a target cumulative dose or by delivering a fixed pre- determined 
dose administered weekly or fortnightly. Most studies have inves-
tigated a dose- response relationship employing at least 2 doses 
with injections administered either intradermally or subcutaneously. 
Efficacy was measured using a standardized clinical scoring system 
of combined nasal/bronchial and ocular symptom and medication 
scores, night- time nasal symptom scores, health- related quality of 
life scores, lung function (in some cases also airway hyperrespon-
siveness), early- and late- phase skin test response, measurement of 
biomarkers such as allergen- specific IgE (sIgE), allergen- specific IgG4 
and facilitated IgE binding assays.
4.2  |  Therapeutic response to peptide AIT
Peptide AIT has been shown to improve clinical responses to aller-
gen challenge either following a natural exposure or during/after a 
controlled exposure in an Environmental Exposure Chamber (EEC) 
alongside alteration in immunological parameters with a significant 
increase in sIgG4 and reduction in sIgE/IgG4 ratio. Recent studies 
have also shown a sustained clinical benefit at years 1– 3 following a 
relatively short course of therapy, alongside persistent immunologi-
cal signals as described above, albeit with a downward trend from 
immediate post- treatment metrics.37,40
4  |    WRAITH And KRISHnA
Ellis et al39 reported a phenomenon of a bell- shaped pharma-
cological response rather than a linear dose- response association 
with grass pollen peptides, highlighting the importance of dose 
titration in early clinical trials to inform robust design of phase III 
trials and beyond. Whilst a cumulative dose of 48 nmol of grass 
peptides (4 or 8 injections) induced a significant therapeutic bene-
fit, a similar (or expected dose- response benefit) response was not 
detected with a higher dose of 96 nmol. This is in contrast to SCIT 
clinical trials involving an alum preparation of Phleum pratense 
which showed a linear dose- response relationship, that is a main-
tenance dose of 100,000 SQ. U was superior to 10,000 SQ. U of 
whole allergen extract in terms of therapeutic efficacy and asso-
ciated with more frequent local and systemic treatment- emergent 
allergic reactions.8
4.3  |  Safety aspects
Whilst recent studies with grass39,41,42 and cat55 peptides have been 
shown to be relatively safe with respect to grade 3 or 4 systemic 
reactions, as per the World Allergy Organization (WAO) grading 
system, others, particularly those involving grass pollen,38 cat47,52 
and birch pollen36 have reported relatively more severe early and 
delayed (>3 h) systemic allergic reactions. Specifically, lower airway 
symptoms with a decline in FEV1 (>30%) have been reported, and 
this has been attributed to a MHC restricted allergen- specific T cell 
activation.57 It has been suggested that the late asthmatic response 
to peptides improves with repeated dosing,52 but this needs confir-
mation. Local injection site reactions have been less frequent and 
relatively less severe.
4.4  |  Putting evidence into context
In summary, peptide AIT is a promising option as an immunomodu-
latory and disease modifying treatment for ARC and asthma, but 
further work is clearly required in well- characterized patients to 
demonstrate its long- term efficacy and safety. Current recom-
mendations with whole allergen extracts of SLIT and SCIT are that 
3 years of treatment is recommended to achieve long- term effi-
cacy.4,5 Whilst there is preliminary and promising evidence that a 
short course of peptide AIT for 4– 6 weeks confers sustained37,40,48 
clinical benefit at years 1– 3, without additional treatment, further 
studies are clearly warranted to determine long- term efficacy with 
optimization of dosing regimens, route of administration (intrader-
mal vs subcutaneous), duration of therapy and safety specifically in 
asthma. Further research is also needed in children in order to deter-
mine the role for peptide AIT not only in established allergic airway 
disease, but also with respect to prevention of asthma and newer 
sensitizations as reported with whole allergen AIT.58 Further re-
search to investigate the efficacy and safety of peptide AIT in house 
dust mite– related ARC and asthma is also needed. Importantly, it 
would be crucial to have a proportionate representation of Black, 
Asian and Minority Ethnic population in peptide AIT clinical trials 
to be able to maintain credibility and generalizability of findings at 
a global level.
Table 1 summarizes key studies in peptide AIT undertaken 
during the last 3 decades and includes details regarding study de-
sign, efficacy and safety. Notably, AIT with Fel d 1– derived pep-
tides showed a stable treatment effect when the clinical response 
was measured employing an EEC. The significance of this effect 
however was challenged in a phase 3 study (ClinicalTrials.gov 
Identifier: NCT01620762; unpublished) in which primary outcome 
was measured by a combined score [CS =Total Rhinoconjunctivitis 
Symptom Score (TRSS) + Rescue Medication Score (RMS)] involv-
ing natural cat allergen exposure over a 3- week period as opposed 
to challenge in an EEC, and no significant differences were de-
tected between the treatment and placebo groups. The reason for 
this study not reaching its desired primary end- point is not clear. 
It is plausible that differences in study methodology, specifically 
method of cat allergen challenge (natural exposure vs EEC) and 
psychosomatic factors might potentially impact in cat allergy clin-
ical trials. This needs due consideration in future peptide AIT clin-
ical trials which should include a combined clinical cum biomarker 
approach, as successfully shown in recent studies involving grass 
pollen peptide AIT.
5  |  PUTATIVE MECHANISMS 
UNDERPINNING PEPTIDE AIT IN ALLERGIC 
AIRWAY DISE A SE AND LESSONS LE ARNT 
FROM PEPTIDE IMMUNOTHER APY IN 
AUTOIMMUNE DISE A SES
5.1  |  Lessons regarding induction of immune 
tolerance from whole allergen AIT studies
The fundamental question relating to effective AIT is the type of im-
mune modulation required to produce effective tolerance towards 
the allergen. On the one hand, there is evidence that administra-
tion of conventional whole allergen- based immunotherapy leads to 
generation of allergen- specific blocking antibodies, that is IgG2 and 
especially IgG4 isotypes that compete for binding antigen and block 
cross- linking of IgE on mast cells. For example, Zhao and colleagues 
have shown that the IgE- blocking factor induced by AIT correlates 
with IgG4 antibodies and a decrease of symptoms in HDM- allergic 
children.59 Furthermore, Shamji and colleagues have shown that 
grass pollen SCIT leads to serum IgG4 inhibitory antibodies that pre-
vent IgE facilitated allergen binding by B cells and hence presenta-
tion to T cells.60 On the other hand, there is evidence that AIT leads 
to the deletion, induction of immunological paralysis (anergy) or im-
mune modulation (alteration of cytokine secretion with respect to 
dampening of Th2 and skewing towards a Th1 or Tr1 phenotype) of 
allergen- specific T cells.61
The key question is which form and mode of delivery of 
the antigenic component of an allergen is safe and effective in 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































    |  15WRAITH And KRISHnA
eliciting either the induction of blocking antibodies or modulation of 
allergen- specific CD4+ T cells. In other words, should AIT involve ac-
tive immunization against the allergen or the induction of tolerance 
mechanisms designed to reduce the immune response to the anti-
gen. One of the main barriers in our current understanding of AIT 
is that there are no reliable immunological correlates or biomarkers 
that determine therapeutic efficacy or indeed those that can accu-
rately predict response to treatment at a patient level. The majority 
of patients remain sensitized to the respective allergen despite de-
riving clinical benefit post- AIT and this phenomenon is also well rec-
ognized in the context of hymenoptera venom immunotherapy (VIT).
5.2  |  Peptides vs whole allergen
The advantage of using peptides rather than intact antigens is that 
peptides generally do not fold into the conformation found in the 
native antigen. As a result, it is most unlikely that a peptide would 
cross- link surface- bound IgE antibodies even if the peptide retained 
a low affinity B cell epitope. Furthermore, this is even less likely with 
short linear peptides that generally form a random coil state.
The aims for a safe, effective and durable impact of AIT are to:
1. Induce immunological tolerance by administering a prepara-
tion that limits the risk of cross- linking IgE and hence causing 
anaphylaxis
2. Develop a treatment strategy that induces effective and long- 
lasting tolerance within months rather than years
3. Reduce the levels of Th2 cells specific for the allergen
4. Increase levels of both Foxp3+ Tregs and IL- 10- secreting Tr1 cells 
responding to the allergen
5. Increase the ratio of IgG4:IgE- secreting B cells so as to increase 
levels of blocking antibodies
The only way to prevent IgE binding to a desensitizing agent 
is to disrupt the conformation of the allergen and its associated B 
cell epitopes. This can be achieved using allergen fragments gener-
ated by enzymatic digestion of the allergen or synthesis of either 
COPs36,37,62 or the design of short synthetic peptides (SPs) repre-
senting dominant T cell epitopes of the allergen.63 Here we will dis-
cuss the pros and cons of the latter two approaches.
5.3  |  COPs vs SPs
COPs contain all of the CD4+ T cell epitopes within the specific al-
lergen and, therefore, have the desired immunomodulatory effect 
irrespective of individual variation in HLA type of the patient. This is 
more difficult with SPs; however, the promiscuous peptide binding 
properties of HLA- DR molecules mean that pan- DR- binding peptides 
can be designed that engage allergen- specific T cells in most indi-
viduals. The fundamental principle between COPs and SPs is, how-
ever, completely different. COPs are designed to be immunogenic, to 
induce immune modulation with induction of IL- 10- producing T cells 
and an increase in the ratio of IgG4:IgE. Importantly, it is known that 
IL- 10- producing T cells such as Tr1 cells promote B cells to produce 
IgG4.
64 IgG4 has two important properties: first, it binds both com-
plement and FcR poorly and hence does not promote inflammation; 
secondly, IgG4 is functionally monovalent since its heavy and light 
chains can undergo half- Ig exchange.65 Currently, COPs are admin-
istered with alum as adjuvant and as a result, there is a theoretical 
risk of both late- phase reaction and anti- drug antibody development 
with repeated administration. Nevertheless, COP treatment of birch 
pollen allergy has led to clinical benefit for two seasons after a single 
pre- seasonal course with demonstrable immunological signals.37
There is increasing evidence that SPs based on the CD4+ T cell 
epitopes of allergens can induce tolerance and mediate suppression 
of the allergic response. The pioneers of this approach in allergy 
were Kay and Larche working with peptides from Fel d 1. They com-
bined seven T cell epitopes from the allergen that was safe to ad-
minister and reduced the immune response to the antigen in allergic 
individuals. A short treatment with Fel d 1 SPs led to reduction in rhi-
noconjunctivitis symptoms that persisted for 2 years from the start 
of the treatment.48 Campbell and colleagues confirmed that this ap-
proach generates IL- 10+ regulatory T cells capable of “linked” sup-
pression of the response to distinct T cell epitopes within the same 
allergen.66 Similar observations have been made in SP- AIT studies of 
bee venom,67 grass allergen39,40 and peanut allergy.68 The induction 
of IL- 10- secreting T cells in these SP- AIT studies is important since 
these Tr1 cells are known to promote IgG4 production. Therefore, 
the induction of blocking antibodies, the aim of active immunization 
with whole allergens or COPs, can also be achieved by tolerance in-
duction with SPs.
5.4  |  Experience from peptide antigen 
immunotherapy in autoimmune diseases
The clinical trials summarized above are reminiscent of similar stud-
ies of SP administration in autoimmune diseases. SPs have been de-
signed for a range of autoimmune diseases and have led to recent 
clinical trials in relapsing MS32 and Graves’ disease.69 A phase 1b 
clinical trial of intradermal immunotherapy with SPs from a myelin 
antigen in saline solution showed a significant decrease in new/per-
sisting T1 gadolinium- enhanced lesions from baseline to week 16, 
returning to baseline values at week 48.32 Similarly, in Graves’ dis-
ease, 7/10 mild to moderate hyperthyroid patients showed improve-
ment in free thyroid hormone levels during the course of treatment. 
Importantly, no unexpected safety signals arose from administration 
of these SPs. It is interesting to note that a short course of treatment 
with SPs in ARC has been shown to induce long- term suppression 
of symptoms,37,40 whereas the use of SPs produces only short- term 
benefit in autoimmune disease.32,69 We propose that this is due to 
the continued exposure of allergic patients to strong antigens and 
the generation of memory B cells producing blocking antibodies. 
Effective use of SPs for autoimmune diseases will require repeated 
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administration to maintain suppression of the relatively weak re-
sponse to their self- antigens.
5.5  |  Mechanisms associated with peptide antigen 
immunotherapy
The Wraith laboratory has used experimental models to reveal the 
detailed mechanism of antigen- specific immunotherapy with SPs 
(Figure 1). Not all T cell epitopes induce tolerance and it transpires 
that peptides must bind directly to MHC II on antigen- presenting 
cells (APCs) to induce tolerance.70 Recent work has shown that 
these antigen processing independent T cell epitopes (apitopes) 
bind preferentially to steady- state dendritic cells (DC) in lymphoid 
organs following subcutaneous injection (unpublished). Steady- 
state DC express low levels of costimulatory molecules and hence 
presentation of T cell epitopes by them is tolerogenic.71 T cells 
responding to SPs presented by steady- state DC become aner-
gic72 and up- regulate expression of inhibitory receptors (CTLA- 
4, TIM3, TIGIT and LAG3) and the transcription factors, MAF 
and NFIL3, that dictate IL- 10 production.73 The resulting Tr1- like 
cells suppress costimulatory molecule expression on neighbour-
ing APC in an IL- 10 dependent manner74 and hence mediate both 
linked and bystander suppression.75 Immune regulation follow-
ing immunotherapy with SPs is reinforced by the generation of 
myeloid- derived suppressor cells (MDSC)76 and IL- 10- secreting 
Breg cells.29,77 Recent work has shown that the generation of im-
munoregulatory Tr1 cells is governed by epigenetic priming of 
genes characteristic of a tolerogenic gene signature.78 It seems 
likely that the mechanisms leading to the generation of Foxp3 and 
Tr1 cells are similar for allergens and self- antigens: we have much 
to learn from the parallel development of antigen- specific immu-
notherapeutic approaches in the fields of allergy and autoimmune 
diseases.
F I G U R E  1  Induction of IL- 10- secreting Tr1 cells by SPs. Soluble peptides administered without adjuvants are presented to naïve or 
effector T cells by antigen- presenting cell (APC), including steady- state dendritic cell (DC). When encountering MHC and antigen on these 
steady- state APC, where levels of costimulatory molecules are limited, T cells differentiate into IL- 10- secreting Tr1 cells. The resulting Tr1 
cells suppress costimulatory molecule expression, mediate linked and bystander suppression of the response of other T cells and promote 
differentiation of myeloid- derived suppressor cells (MDSC) and IL- 10- secreting Breg cells. Furthermore, Tr1 cells induce class switching to 
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6  |  FUTURE DE VELOPMENT OF PEPTIDE 
IMMUNOTHER APY FOR TRE ATMENT OF 
ALLERGY AND A STHMA
The time required to achieve effective tolerance by AIT for aller-
gic airway diseases is currently months to years. Based on initial 
results of peptide therapy, however, it appears that tolerance to 
allergens is achievable with a short course of peptide AIT. Even so, 
there are likely to be combination therapies that could enhance 
AIT without disrupting tolerance induction. Whilst the use of 
steroids can inhibit T cell activation, previous studies have shown 
that combined dexamethasone and vitamin D3 promotes Tr1 cell 
differentiation.79 In addition, antibodies targeting effector arms 
of the allergic response, including anti- IgE or anti- IL- 5, could be 
given whilst concurrently inducing tolerance by peptide therapy. 
Furthermore, it may now be possible to reduce levels of plasma 
cells using anti- CD38 antibodies, as tested recently in systemic 
lupus erythematosus.80
As mentioned above, COPs and SPs depend on fundamentally 
different mechanisms of active immunization versus tolerization, re-
spectively. It is possible that the effect of COPs could be improved by 
combination with virosomes. Anergis, the company producing COPs, 
has announced improved efficacy of their treatment when combined 
with virosomes from Mymetics, in an unpublished pre- clinical study. 
A number of groups are investigating different ways to deliver SPs 
for treatment of autoimmune diseases.81 These include presentation 
by tolerogenic DCs, generated in vitro and then transferred back to 
the patient; delivery on red blood cells or nanoparticles designed to 
target the tolerogenic environment of the liver; combination with 
immunosuppressive drugs in nanoparticles or delivery on MHC 
coated nanoparticles. Although each of these approaches is tried 
and tested in pre- clinical models of autoimmune disease, none have 
yet been designed to treat allergic diseases. Any one of these ap-
proaches could improve on currently available approaches.
At present, we know little about the mechanism of action (MoA) 
of novel AIT approaches being test in clinical trials. We need to de-
fine the optimal conditions for induction of tolerance, immune cor-
relates of effective desensitization, kinetics of tolerance, longevity 
of disease suppression and molecular basis of effective immunother-
apy. We now have the tools allowing us to focus on antigen- specific 
cells isolated from patients82 using peptide- MHC multimers and 
high- throughput transcriptional profiling to define MoA. These tools 
enable us to address the critical questions listed above. Furthermore, 
we must use precision medicine approaches to define why each pa-
tient does or does not respond to treatment and hence allow better 
patient stratification.
In conclusion, we are now beginning to understand the MoA of 
conventional and novel approaches to AIT. We propose that peptide 
AIT will greatly enhance the safety and ultimately compliance levels 
in those treated and hence improve management of this rapidly in-
creasing group of diseases. A number of distinct approaches are in 
the pipeline and when proven to be both safe and effective these 
will greatly improve the armamentarium of the allergist.
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terleukin 10- producing regulatory CD4(+) T cells is induced by im-
munosuppressive drugs and inhibited by T helper type 1 (Th1)- and 
Th2- inducing cytokines. J Exp Med. 2002;195(5):603- 616.
 80. Ostendorf L, Burns M, Durek P, et al. Targeting CD38 with daratu-
mumab in refractory systemic lupus erythematosus. N Engl J Med. 
2020;383(12):1149- 1155.
 81. Wraith DC. Designing antigens for the prevention and treatment of 
autoimmune diseases. Curr Opin Chem Eng. 2018;19:35- 42.
 82. Ryan JF, Hovde R, Glanville J, et al. Successful immunotherapy 
induces previously unidentified allergen- specific CD4+ T- cell sub-
sets. Proc Natl Acad Sci USA. 2016;113(9):E1286- E1295.
How to cite this article: Wraith DC, Krishna MT. Peptide 
allergen- specific immunotherapy for allergic airway 
diseases— State of the art. Clin Exp Allergy. 2021;00:1–19. 
https://doi.org/10.1111/cea.13840
